Ya‐xin Liu

SEP 8, 2026 · JOURNAL ARTICLE

Safety, Pharmacokinetics and Pharmacodynamics of the GLP ‐1/ GIP / GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo‐Controlled Phase 1a/1b Study

Diabetes Obesity and Metabolism

First-in-human Phase 1a/1b trial with primary endpoints of safety and tolerability; pharmacodynamic weight loss and metabolic findings are encouraging but uncontrolled comparisons in a small, early-phase study cannot yet support practice changes.